Headache, dizziness, excessive tiredness, myalgia, anosmia/hyposmia, and ageusia/dysgeusia are common nonspecific neurological manifestations during early COVID-19 disease found in the majority of patients. Less frequent but more severe and specific neurological manifestations include Guillain–Barré syndrome, encephalopathy, encephalitis/meningitis, epileptic seizures, and cerebrovascular events. Beyond standard neurological examination, these require a more extensive work-up, including cerebrospinal fluid assessment, neurophysiological evaluation, neuroimaging, and cognitive testing. Symptomatic treatment is advisable unless the neurological complication’s immune pathogenesis is proven. The authors underline that neurological manifestations of COVID-19 occur during the acute, para-infectious, and ‘recovery’ phase and that therapeutic management depends on the clinical presentation and neurological work-up.
Schweitzer F, et al. Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis. Curr Opin Neurol. 2021 Mar 11. doi: 10.1097/WCO.0000000000000930